Currently, alvocidib, marketed as a CDK9 inhibitor, is being trialled by Tolero Pharmaceuticals for the treatment of acute myeloid leukaemia (AML) (Clinicaltrials.gov identifiers: NCT03298984; NCT03969420; NCT02520011). The gene discussed is CDK9; the disease is acute myeloid leukemia.